Enjoy complimentary customisation on priority with our Enterprise License!
The global gonorrhea therapeutics market size is estimated to grow/decline by USD 541.5 million at a CAGR of 5.55% between 2022 and 2027. In the Global Gonorrhea Therapeutics Market, the increasing utilization of advanced diagnostic tests, notably nucleic acid amplification tests (NAATs), marks a significant development. These tests play a crucial role in driving demand for gonorrhea therapeutics by accurately detecting Neisseria gonorrhoeae infection. Moreover, diagnostic screening, facilitated by these tests, emerges as a vital strategy in curbing the spread of the infection to the upper genital tract, particularly considering the often asymptomatic nature of gonorrhea, especially in women. With traditional culture and nucleic acid hybridization also available for confirmation, the advent of NAATs is expected to positively impact the market, enhancing diagnosis accuracy and treatment efficacy. This market research and growth report also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 to 2022, besides analyzing the current market scenario.
To learn more about this report, Download Report Sample
The Hospital pharmacies segment plays a crucial role in ensuring the safe and accurate administration of gonorrhea therapeutics, particularly in hospital settings where patients are diagnosed with this STD. Retail pharmacies and online pharmacies also contribute to the distribution of these medications to women and men, who are equally affected by gonorrhea. Gonorrhea can lead to complications such as pelvic inflammatory disease, HIV, gonococcal arthritis, gonococcal meningitis, endocarditis, and infertility.
Get a glance at the market contribution of various segments Download PDF Sample
The hospital pharmacies segment was the largest and was valued at USD 696.80 million in 2018. The importance of effective gonorrhea treatment extends beyond individual health, as untreated cases can contribute to the spread of this infectious disease. The challenge of addressing antimicrobial resistance in gonorrhea treatment requires ongoing research and development efforts. The global market for gonorrhea therapeutics is expected to grow as new treatments are discovered and existing ones are adapted to address the evolving nature of drug-resistant gonorrhea.
Monotherapy
The Gonorrhea Therapeutics Market encompasses various treatment approaches, with monotherapy being a prominent segment. This approach employs a single drug, such as cefixime or ceftriaxone, to address the disease. National campaigns and public health initiatives prioritize monotherapy due to its advantages, including lower side effects, improved tolerability, and the absence of drug-drug interactions. Gonorrhea, an STD, can lead to complications like HIV infection, particularly among adolescents. Government therapies and clinical settings, including STD clinics, play a crucial role in ensuring access to effective treatments. The monotherapy segment's growth is further driven by the first-line regimen of 400 mg cefixime orally or 125-1000 mg ceftriaxone IM/IV. However, the dual therapy segment has gained significance due to the emergence of antibiotic resistance. Such factors will increase the segment growth in this market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period.
The Gonorrhea Therapeutics Market encompasses various interventions aimed at addressing the prevalence and complications of this sexually transmitted disease (STD). National campaigns, spearheaded by governments and health organizations, play a crucial role in raising awareness and promoting screening for Gonorrhea and other STDs, particularly among high-risk populations such as adolescents. Gonorrhea is often co-infected with HIV, which can lead to more severe health consequences. The HIV-Gonorrhea coinfection can result in increased transmission rates, complications during pregnancy, and worsened clinical outcomes. Government therapies, including antibiotics and vaccines, are essential in mitigating the impact of these infections.
Moreover, the social stigma surrounding STDs, including Gonorrhea, can discourage individuals from seeking treatment at STD clinics. This reluctance can lead to the spread of the disease and complications, such as Urogenital gonorrhea infection, Chlamydia infection, Secondary syphilis, and Congenital syphilis. The dual therapy segment, which combines two antibiotics for improved efficacy, is a first-line regimen for treating Gonorrhea. Clinical Infectious Diseases, a leading peer-reviewed journal, regularly publishes research on Gonorrhea and other STDs, providing valuable insights into the disease's epidemiology, diagnosis, and treatment. Human papillomavirus (HPV), another common STD, can increase the risk of Gonorrhea and other STDs. Effective HPV vaccines can help prevent the spread of these infections and reduce the overall burden of STDs.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Apotex Inc: The company offers gonorrhea therapeutics such as Apotex Ceftriaxone Injection.
Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cipla Inc., Debiopharm International SA, Entasis Therapeutics, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Mayne Pharma Group Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Therapyx Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The Gonorrhea Therapeutics Market encompasses the development, production, and distribution of antibiotics used to treat Neisseria gonorrhea infections, including drug-resistant strains. Ceftriaxone and Cefixime are commonly used oral antibiotics for the treatment of uncomplicated Gonococcal Infection. However, the emergence of antibiotic-resistant strains, such as Neisseria gonorrhea, poses a significant challenge to current therapies. Enterprising organizations, like Entasis Therapeutics, are pioneering new approaches to combat antimicrobial resistance. Monotherapy and dual therapy are the primary treatment strategies for gonorrhea. Monotherapy involves the use of a single antibiotic, while dual therapy involves the use of two antibiotics. The choice of therapy depends on the severity of the infection and the presence of co-infections, such as Chlamydia trachomatis or HIV. Hospital pharmacies and retail pharmacies play crucial roles in the distribution of gonorrhea therapeutics. These establishments ensure that patients receive the appropriate antibiotics in a timely and efficient manner. Gonorrhea infections can lead to complications, such as Pelvic inflammatory disease, Gonococcal Arthritis, Gonococcal Meningitis, Endocarditis, and HIV co-infection. Effective therapeutics are essential to prevent these complications and mitigate the spread of antibiotic-resistant strains.
The global concern over the increasing incidence of gonorrhea is a key driver shaping the market. In 2022, the US reported 648,056 cases of gonorrhea, making it the second most common Sexually Transmitted Disease (STD) after Chlamydia trachomatis. The prevalence rate of gonorrhea has been higher in women than men in recent years. Drug-resistance gonorrhea poses a significant challenge, with Ceftriaxone and Cefixime, commonly used antibiotics, showing decreased efficacy. Antimicrobial resistance is a growing concern, with Entasis Therapeutics' Zoliflodacin and Neisseria Gonorrhoeae's DNA synthesis inhibitor, showing promise as potential treatments for uncomplicated gonococcal infections.
However, the complexities of treating drug-resistant gonorrhea necessitate monotherapy or dual therapy. Asymptomatic cases often go undetected, leading to complications such as pelvic inflammatory disease, HIV co-infection, gonococcal arthritis, gonococcal meningitis, endocarditis, and infertility. The treatment landscape includes hospital pharmacies, retail pharmacies, and online pharmacies, offering oral and injectable antibiotics like Ceftriaxone, Cefixime, Azithromycin, and the antibiotic-resistant gonococcal strain-targeting antibiotic, Zoliflodacin. Such factors will increase the market growth during the forecast period.
A key trend shaping the market growth is the advent of vaccines for the prevention of gonorrhea. There is a growing concern across the world regarding the prevalence of gonorrhea as it is significantly impacting the reproductive health of people and increasing the spread of the human immunodeficiency virus (HIV). due to the rapid emergence of antibiotic-resistant strains of this bacterium., the conventional treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae.
As a result, the prevention of the disease seems to be the ideal approach for containing the spread of Neisseria gonorrhoeae. Therefore, there is an increasing development of novel vaccines that can prevent gonorrhea. For example, the antigens contained in the MeNZB vaccine, which was originally developed to stop the meningitis outbreak in New Zealand during 2004-2006, have shown some clinical efficacy against the gonococcal bacteria. Hence, such factors are positively impacting the market which in turn will drive the market growth during the forecast period.
Neisseria gonorrhea bacteria, the causative agent of gonorrhea, continue to pose a significant challenge to the global therapeutics market due to the emergence of antibiotic-resistant strains. Drug-resistance gonorrhea, a concerning trend, has led to the CDC's recommendation of ceftriaxone and azithromycin as the first-line treatment for gonorrhea in the US. The increase in minimum inhibitory concentrations (MIC) for cefixime is indicative of the growing prevalence of antibiotic-resistant strains. Approximately two million people in the US are affected by antibiotic-resistant infections yearly, resulting in at least 23,000 deaths. Entasis Therapeutics' zoliflodacin, an antibiotic targeting DNA synthesis in Neisseria Gonorrhoeae, is a promising candidate for monotherapy or dual therapy in treating drug-resistant gonorrhea. Chlamydia trachomatis, another common sexually transmitted disease (STD), often co-exists with gonorrhea, necessitating comprehensive treatment approaches. STDs, including gonorrhea and chlamydia, can lead to complications such as pelvic inflammatory disease, infertility, HIV, and other severe health issues.
Moreover, ceftriaxone and azithromycin are available in various pharmacy channels, including hospital, retail, and online, catering to the diverse needs of patients. These antibiotics are administered orally or injectable, depending on the severity of the infection and the patient's condition. Asymptomatic cases are crucial to address to prevent the spread of antibiotic-resistant gonococcal strains. The global fight against antibiotic resistance requires continuous research and development of new antibiotics and alternative treatment methods. The importance of adhering to prescribed antibiotic regimens cannot be overstated in mitigating the risk of antibiotic resistance. Infectious diseases, including gonorrhea, pose a significant threat to public health and necessitate a collaborative effort from healthcare providers, policymakers, and the general population. Such factors will hinder the market growth during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market is significant due to the increasing prevalence of Gonorrhea worldwide. The market is driven by factors such as the rising awareness of sexually transmitted diseases (STDs) and the availability of effective treatments. The market is also influenced by the emergence of antibiotic-resistant strains of Gonorrhea, necessitating the development of new therapeutics. Governments and non-profit organizations are investing in research and development to address the issue of antibiotic resistance. Infectious disease companies are focusing on the development of novel therapies, including monoclonal antibodies and long-acting injectables. The market for Gonorrhea Therapeutics is expected to grow in the coming years due to the increasing incidence of the disease and the need for effective treatments.
Moreover, the market is also expected to be driven by the development of new therapies and the increasing awareness of STDs. The use of advanced technologies such as biotechnology and molecular diagnostics is expected to revolutionize the Gonorrhea Therapeutics market. The market is also expected to be influenced by regulatory approvals and reimbursement policies. In conclusion, the Gonorrhea Therapeutics market is a growing and dynamic field, driven by the increasing incidence of Gonorrhea and the need for effective treatments. The market is expected to be influenced by various factors, including regulatory approvals, reimbursement policies, and the development of new therapies. Such factors will increase the market growth during the forecast period.
Gonorrhea Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
170 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.55% |
Market growth 2024-2028 |
USD 541.5 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
5.15 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key countries |
US, Germany, China, UK, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cipla Inc., Debiopharm International SA, Entasis Therapeutics, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Mayne Pharma Group Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Therapyx Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.